Annual report pursuant to Section 13 and 15(d)

Schedule of Accrued Expenses (Details)

v3.22.0.1
Schedule of Accrued Expenses (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Payroll and incentives $ 1,343,000 $ 1,094,000
General and administrative expenses 195,000 280,000
Research and development expenses 381,000 778,000
Other Accrued Liabilities, Current [1] 932,000 643,000
Total $ 2,850,888 $ 2,795,329
[1] At December 31, 2021, the balance included approximately $899 thousand related to the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech feasibility study agreement. At December 31, 2020, the balance included approximately $577 thousand related to the CFF Agreement’s deferred liability and approximately $67 thousand of deferred revenue related to the Genentech feasibility study agreement.